Cargando…

Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial

BACKGROUND: Tolvaptan (TLV) is reported to improve diuretic effects in patients with chronic kidney disease (CKD) when furosemide (FUR) is not sufficiently effective. However, it is not clear whether TLV addition is effective for advanced CKD patients with heart failure. METHODS: An open-label, para...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komiya, Shiro, Katsumata, Mari, Ozawa, Moe, Haze, Tatsuya, Kawano, Rina, Ohki, Yuki, Suzuki, Shota, Kobayashi, Yusuke, Fujiwara, Akira, Saka, Sanae, Tamura, Kouichi, Hirawa, Nobuhito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385808/ https://www.ncbi.nlm.nih.gov/pubmed/35471469 http://dx.doi.org/10.1007/s10157-022-02224-x

Ejemplares similares

Association of the ratio of visceral-to-subcutaneous fat volume with renal function among patients with primary aldosteronism
por: Haze, Tatsuya, et al.
Publicado: (2021)

The implication of calf circumference and grip strength in osteoporosis and bone mineral density among hemodialysis patients
por: Ozawa, Moe, et al.
Publicado: (2022)

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure
por: Katsumata, Mari, et al.
Publicado: (2017)

The effects of anti-hypertensive drugs and the mechanism of hypertension in vascular smooth muscle cell-specific ATP2B1 knockout mice
por: Okuyama, Yuki, et al.
Publicado: (2018)

Reduced secretion of parathyroid hormone and hypocalcemia in systemic heterozygous ATP2B1-null hypertensive mice
por: Ehara, Yosuke, et al.
Publicado: (2018)

Efficacy of cyclosporine combination therapy for new-onset minimal change nephrotic syndrome in adults
por: Fujiwara, Akira, et al.
Publicado: (2014)

Relationship between Arterial Stiffness and Blood Pressure Drop During the Sit-to-stand Test in Patients with Diabetes Mellitus
por: Kobayashi, Yusuke, et al.
Publicado: (2017)

Influence of Functional Impairment on Prognosis in Hospitalized Elderly Patients on Dialysis
por: Tamura, Kouichi, et al.
Publicado: (2023)

Relationship between silent brain infarction and chronic kidney disease
por: Kobayashi, Mayumi, et al.
Publicado: (2009)

Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients
por: Kanai, Daisuke, et al.
Publicado: (2022)

SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan
por: Kanai, Daisuke, et al.
Publicado: (2022)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Kidney Diseases Enhance Expression of Tetraspanin-8: A Possible Protective Effect against Tubular Injury
por: Hirukawa, Takashi, et al.
Publicado: (2014)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Predictors of in-hospital mortality in elderly patients with heart failure treated with tolvaptan
por: Kobayashi, Masakazu, et al.
Publicado: (2023)

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
por: Gibson, Andrew, et al.
Publicado: (2020)

Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial
por: Kawai, Yuki, et al.
Publicado: (2021)

Enhancement of intrarenal plasma membrane calcium pump isoform 1 expression in chronic angiotensin II‐infused mice
por: Wakui, Hiromichi, et al.
Publicado: (2017)

Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
por: Mizuno, Hiroki, et al.
Publicado: (2017)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure
por: Nomura, Ryohei, et al.
Publicado: (2023)

Efficacy of tolvaptan in an infant with syndrome of inappropriate antidiuretic hormone secretion associated with holoprosencephaly: A case report
por: Mori, Mari, et al.
Publicado: (2023)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021)

Tolvaptan and its potential in the treatment of hyponatremia
por: Dixon, Megan B, et al.
Publicado: (2008)

V2 Receptor Antagonist; Tolvaptan
por: Yi, Joo-Hark, et al.
Publicado: (2011)

Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis
por: Iwamoto, Takuya, et al.
Publicado: (2016)

The management of polycystic liver disease by tolvaptan
por: Takenaka, Tsuneo, et al.
Publicado: (2020)

Tolvaptan for the Treatment of Elephantiasis Nostras Verrucosa
por: Eda, Yuko, et al.
Publicado: (2019)

Long-term administration of Tolvaptan to patients with decompensated cirrhosis
por: Kanayama, Kengo, et al.
Publicado: (2020)

Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone
por: YAMAMOTO, Hiroka, et al.
Publicado: (2023)

A novel hydrogel sheet prevents postoperative pancreatic fistula in a rat model
por: Kemmochi, Akira, et al.
Publicado: (2020)

Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria
por: Takagi, Koji, et al.
Publicado: (2017)

Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
por: Shiba, Shunsuke, et al.
Publicado: (2020)

Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model
por: Tanabe, Norikazu, et al.
Publicado: (2017)

Angiotensin Receptor–Binding Protein ATRAP/Agtrap Inhibits Metabolic Dysfunction With Visceral Obesity
por: Maeda, Akinobu, et al.
Publicado: (2013)

Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention
por: Masuda, Takahiro, et al.
Publicado: (2016)

Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study
por: Nakada, Yasuki, et al.
Publicado: (2015)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7stpq8114l4u38jiucftbfl3bf